Search

Your search keyword '"Saussez, S."' showing total 518 results
Start Over Author "Saussez, S."

Refine your results

518 results on '"Saussez, S."'

5. Preexposure of MCF-7 breast cancer cell line to dexamethasone alters the cytotoxic effect of paclitaxel but not 5-fluorouracil or epirubicin chemotherapy

Author

Buxant F, Kindt N, Noël JC, Laurent G, and Saussez S

Subjects
Dexamethasone, 5-Fluorouracil, Epirubicin, Paclitaxel, MCF-7, Chemotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Frederic Buxant,1,* Nadège Kindt,2,* Jean-Christophe Noël,3 Guy Laurent,4,† Sven Saussez2 1Department of Gynaecology, Iris South Hospital, Brussels, 2Department of Anatomy, Laboratory of Anatomy and Cell Biology, Faculty of Medicine and Pharmacy, University of Mons, Mons, 3Department of Pathology, Erasme Hospital, Free University of Brussels (ULB), Brussels, 4Department of Histology, Laboratory of Histology, Faculty of Medicine and Pharmacy, University of Mons, Mons, Belgium *These authors contributed equally to this work †Dr Guy Laurent passed away on August 9, 2016 Purpose: Glucocorticoids (GCs) are often administered prior to any chemotherapeutics to prevent the secondary effects of anticancer agents. Glucocorticoid receptors (GRs) are expressed in several types of cancer cells, particularly in several histological types of breast cancer. Activation of GRs is not associated with any specific cellular response. Both proapoptotic and ­antiapoptotic responses have been observed, depending on the study or the type of breast cancer cells. Therefore, it is of relevance to investigate the possible modulation of apoptotic effect of chemotherapeutic agents when cancerous cells have previously been exposed to GCs. Methods: In vitro cell growth was assayed by counting MCF-7 cells upon exposure to epirubicin (25 nM), 5-fluorouracil (5-FU) (15 µM), and paclitaxel (15 nM), either with or without prior exposure to the GC dexamethasone (Dex) (100 nM).Results: Following preexposure to Dex, the antiapoptotic activity of paclitaxel was significantly reduced by 8.5% (p

Published
2017

6. Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis

Author

Singh, B, Lant, S, Cividini, S, Cattrall, J, Goodwin, L, Benjamin, L, Michael, B, Khawaja, A, Matos, A, Alkeridy, W, Pilotto, A, Lahiri, D, Rawlinson, R, Mhlanga, S, Lopez, E, Sargent, B, Somasundaran, A, Tamborska, A, Webb, G, Younas, K, Al Sami, Y, Babu, H, Banks, T, Cavallieri, F, Cohen, M, Davies, E, Dhar, S, Modol, A, Farooq, H, Harte, J, Hey, S, Joseph, A, Karthikappallil, D, Kassahun, D, Lipunga, G, Mason, R, Minton, T, Mond, G, Poxon, J, Rabas, S, Soothill, G, Zedde, M, Yenkoyan, K, Brew, B, Contini, E, Cysique, L, Zhang, X, Maggi, P, van Pesch, V, Lechien, J, Saussez, S, Heyse, A, Brito Ferreira, M, Soares, C, Elicer, I, Eugenin-Von Bernhardi, L, Reyes, W, Yin, R, Azab, M, Abd-Allah, F, Elkady, A, Escalard, S, Corvol, J, Delorme, C, Tattevin, P, Bigaut, K, Lorenz, N, Hornuss, D, Hosp, J, Rieg, S, Wagner, D, Knier, B, Lingor, P, Winkler, A, Sharifi-Razavi, A, Moein, S, Seyed Alinaghi, S, Jamali Moghadam Siahkali, S, Morassi, M, Padovani, A, Giunta, M, Libri, I, Beretta, S, Ravaglia, S, Foschi, M, Calabresi, P, Primiano, G, Servidei, S, Mercuri, N, Liguori, C, Pierantozzi, M, Sarmati, L, Boso, F, Garazzino, S, Mariotto, S, Patrick, K, Costache, O, Pincherle, A, Klok, F, Meza, R, Cabreira, V, Valdoleiros, S, Oliveira, V, Kaimovsky, I, Guekht, A, Koh, J, Diaz, E, Barrios-Lopez, J, Guijarro-Castro, C, Beltran-Corbellini, A, Martinez-Poles, J, Diezma-Martin, A, Morales-Casado, M, Garcia, S, Breville, G, Coen, M, Uginet, M, Bernard-Valnet, R, Pasquier, R, Kaya, Y, Abdelnour, L, Rice, C, Morrison, H, Defres, S, Huda, S, Enright, N, Hassell, J, D'Anna, L, Benger, M, Sztriha, L, Raith, E, Chinthapalli, K, Nortley, R, Paterson, R, Chandratheva, A, Werring, D, Dervisevic, S, Harkness, K, Pinto, A, Jillella, D, Beach, S, Gunasekaran, K, Ferreira Da Silva, I, Nalleballe, K, Santoro, J, Scullen, T, Kahn, L, Kim, C, Thakur, K, Jain, R, Umapathi, T, Nicholson, T, Sejvar, J, Hodel, E, Smith, C, Solomon, T, Singh B., Lant S., Cividini S., Cattrall J. W. S., Goodwin L. C., Benjamin L., Michael B. D., Khawaja A., Matos A. D. M. B., Alkeridy W., Pilotto A., Lahiri D., Rawlinson R., Mhlanga S., Lopez E. C., Sargent B. F., Somasundaran A., Tamborska A., Webb G., Younas K., Al Sami Y., Babu H., Banks T., Cavallieri F., Cohen M., Davies E., Dhar S., Modol A. F., Farooq H., Harte J., Hey S., Joseph A., Karthikappallil D., Kassahun D., Lipunga G., Mason R., Minton T., Mond G., Poxon J., Rabas S., Soothill G., Zedde M., Yenkoyan K., Brew B., Contini E., Cysique L., Zhang X., Maggi P., van Pesch V., Lechien J., Saussez S., Heyse A., Brito Ferreira M. L., Soares C. N., Elicer I., Eugenin-Von Bernhardi L., Reyes W. N., Yin R., Azab M. A., Abd-Allah F., Elkady A., Escalard S., Corvol J. -C., Delorme C., Tattevin P., Bigaut K., Lorenz N., Hornuss D., Hosp J., Rieg S., Wagner D., Knier B., Lingor P., Winkler A. S., Sharifi-Razavi A., Moein S. T., Seyed Alinaghi S. A., Jamali Moghadam Siahkali S., Morassi M., Padovani A., Giunta M., Libri I., Beretta S., Ravaglia S., Foschi M., Calabresi P., Primiano G., Servidei S., Mercuri N. B., Liguori C., Pierantozzi M., Sarmati L., Boso F., Garazzino S., Mariotto S., Patrick K. N., Costache O., Pincherle A., Klok F. A., Meza R., Cabreira V., Valdoleiros S. R., Oliveira V., Kaimovsky I., Guekht A., Koh J., Diaz E. F., Barrios-Lopez J. M., Guijarro-Castro C., Beltran-Corbellini A., Martinez-Poles J., Diezma-Martin A. M., Morales-Casado M. I., Garcia S. G., Breville G., Coen M., Uginet M., Bernard-Valnet R., Pasquier R. D., Kaya Y., Abdelnour L. H., Rice C., Morrison H., Defres S., Huda S., Enright N., Hassell J., D'Anna L., Benger M., Sztriha L., Raith E., Chinthapalli K., Nortley R., Paterson R., Chandratheva A., Werring D. J., Dervisevic S., Harkness K., Pinto A., Jillella D., Beach S., Gunasekaran K., Ferreira Da Silva I. R., Nalleballe K., Santoro J., Scullen T., Kahn L., Kim C. Y., Thakur K. T., Jain R., Umapathi T., Nicholson T. R., Sejvar J. J., Hodel E. M., Smith C. T., Solomon T., Singh, B, Lant, S, Cividini, S, Cattrall, J, Goodwin, L, Benjamin, L, Michael, B, Khawaja, A, Matos, A, Alkeridy, W, Pilotto, A, Lahiri, D, Rawlinson, R, Mhlanga, S, Lopez, E, Sargent, B, Somasundaran, A, Tamborska, A, Webb, G, Younas, K, Al Sami, Y, Babu, H, Banks, T, Cavallieri, F, Cohen, M, Davies, E, Dhar, S, Modol, A, Farooq, H, Harte, J, Hey, S, Joseph, A, Karthikappallil, D, Kassahun, D, Lipunga, G, Mason, R, Minton, T, Mond, G, Poxon, J, Rabas, S, Soothill, G, Zedde, M, Yenkoyan, K, Brew, B, Contini, E, Cysique, L, Zhang, X, Maggi, P, van Pesch, V, Lechien, J, Saussez, S, Heyse, A, Brito Ferreira, M, Soares, C, Elicer, I, Eugenin-Von Bernhardi, L, Reyes, W, Yin, R, Azab, M, Abd-Allah, F, Elkady, A, Escalard, S, Corvol, J, Delorme, C, Tattevin, P, Bigaut, K, Lorenz, N, Hornuss, D, Hosp, J, Rieg, S, Wagner, D, Knier, B, Lingor, P, Winkler, A, Sharifi-Razavi, A, Moein, S, Seyed Alinaghi, S, Jamali Moghadam Siahkali, S, Morassi, M, Padovani, A, Giunta, M, Libri, I, Beretta, S, Ravaglia, S, Foschi, M, Calabresi, P, Primiano, G, Servidei, S, Mercuri, N, Liguori, C, Pierantozzi, M, Sarmati, L, Boso, F, Garazzino, S, Mariotto, S, Patrick, K, Costache, O, Pincherle, A, Klok, F, Meza, R, Cabreira, V, Valdoleiros, S, Oliveira, V, Kaimovsky, I, Guekht, A, Koh, J, Diaz, E, Barrios-Lopez, J, Guijarro-Castro, C, Beltran-Corbellini, A, Martinez-Poles, J, Diezma-Martin, A, Morales-Casado, M, Garcia, S, Breville, G, Coen, M, Uginet, M, Bernard-Valnet, R, Pasquier, R, Kaya, Y, Abdelnour, L, Rice, C, Morrison, H, Defres, S, Huda, S, Enright, N, Hassell, J, D'Anna, L, Benger, M, Sztriha, L, Raith, E, Chinthapalli, K, Nortley, R, Paterson, R, Chandratheva, A, Werring, D, Dervisevic, S, Harkness, K, Pinto, A, Jillella, D, Beach, S, Gunasekaran, K, Ferreira Da Silva, I, Nalleballe, K, Santoro, J, Scullen, T, Kahn, L, Kim, C, Thakur, K, Jain, R, Umapathi, T, Nicholson, T, Sejvar, J, Hodel, E, Smith, C, Solomon, T, Singh B., Lant S., Cividini S., Cattrall J. W. S., Goodwin L. C., Benjamin L., Michael B. D., Khawaja A., Matos A. D. M. B., Alkeridy W., Pilotto A., Lahiri D., Rawlinson R., Mhlanga S., Lopez E. C., Sargent B. F., Somasundaran A., Tamborska A., Webb G., Younas K., Al Sami Y., Babu H., Banks T., Cavallieri F., Cohen M., Davies E., Dhar S., Modol A. F., Farooq H., Harte J., Hey S., Joseph A., Karthikappallil D., Kassahun D., Lipunga G., Mason R., Minton T., Mond G., Poxon J., Rabas S., Soothill G., Zedde M., Yenkoyan K., Brew B., Contini E., Cysique L., Zhang X., Maggi P., van Pesch V., Lechien J., Saussez S., Heyse A., Brito Ferreira M. L., Soares C. N., Elicer I., Eugenin-Von Bernhardi L., Reyes W. N., Yin R., Azab M. A., Abd-Allah F., Elkady A., Escalard S., Corvol J. -C., Delorme C., Tattevin P., Bigaut K., Lorenz N., Hornuss D., Hosp J., Rieg S., Wagner D., Knier B., Lingor P., Winkler A. S., Sharifi-Razavi A., Moein S. T., Seyed Alinaghi S. A., Jamali Moghadam Siahkali S., Morassi M., Padovani A., Giunta M., Libri I., Beretta S., Ravaglia S., Foschi M., Calabresi P., Primiano G., Servidei S., Mercuri N. B., Liguori C., Pierantozzi M., Sarmati L., Boso F., Garazzino S., Mariotto S., Patrick K. N., Costache O., Pincherle A., Klok F. A., Meza R., Cabreira V., Valdoleiros S. R., Oliveira V., Kaimovsky I., Guekht A., Koh J., Diaz E. F., Barrios-Lopez J. M., Guijarro-Castro C., Beltran-Corbellini A., Martinez-Poles J., Diezma-Martin A. M., Morales-Casado M. I., Garcia S. G., Breville G., Coen M., Uginet M., Bernard-Valnet R., Pasquier R. D., Kaya Y., Abdelnour L. H., Rice C., Morrison H., Defres S., Huda S., Enright N., Hassell J., D'Anna L., Benger M., Sztriha L., Raith E., Chinthapalli K., Nortley R., Paterson R., Chandratheva A., Werring D. J., Dervisevic S., Harkness K., Pinto A., Jillella D., Beach S., Gunasekaran K., Ferreira Da Silva I. R., Nalleballe K., Santoro J., Scullen T., Kahn L., Kim C. Y., Thakur K. T., Jain R., Umapathi T., Nicholson T. R., Sejvar J. J., Hodel E. M., Smith C. T., and Solomon T.

Abstract

Background Neurological COVID-19 disease has been reported widely, but published studies often lack information on neurological outcomes and prognostic risk factors. We aimed to describe the spectrum of neurological disease in hospitalised COVID-19 patients; characterise clinical outcomes; and investigate factors associated with a poor outcome. Methods We conducted an individual patient data (IPD) meta-analysis of hospitalised patients with neurological COVID-19 disease, using standard case definitions. We invited authors of studies from the first pandemic wave, plus clinicians in the Global COVID-Neuro Network with unpublished data, to contribute. We analysed features associated with poor outcome (moderate to severe disability or death, 3 to 6 on the modified Rankin Scale) using multivariable models. Results We included 83 studies (31 unpublished) providing IPD for 1979 patients with COVID-19 and acute new-onset neurological disease. Encephalopathy (978 [49%] patients) and cerebrovascular events (506 [26%]) were the most common diagnoses. Respiratory and systemic symptoms preceded neurological features in 93% of patients; one third developed neurological disease after hospital admission. A poor outcome was more common in patients with cerebrovascular events (76% [95% CI 67–82]), than encephalopathy (54% [42–65]). Intensive care use was high (38% [35–41]) overall, and also greater in the cerebrovascular patients. In the cerebrovascular, but not encephalopathic patients, risk factors for poor outcome included breathlessness on admission and elevated D-dimer. Overall, 30-day mortality was 30% [27–32]. The hazard of death was comparatively lower for patients in the WHO European region. Interpretation Neurological COVID-19 disease poses a considerable burden in terms of disease outcomes and use of hospital resources from prolonged intensive care and inpatient admission; preliminary data suggest these may differ according to WHO regions and country income levels. The dif

Published
2022

9. Correlations Between Olfactory Psychophysical Scores and SARS-CoV-2 Viral Load in COVID-19 Patients

Author

Vaira, L, Deiana, G, Lechien, J, De Vito, A, Cossu, A, Dettori, M, Del Rio, A, Saussez, S, Madeddu, G, Babudieri, S, Fois, A, Cocuzza, C, Hopkins, C, De Riu, G, Piana, A, Vaira L. A., Deiana G., Lechien J. R., De Vito A., Cossu A., Dettori M., Del Rio A., Saussez S., Madeddu G., Babudieri S., Fois A. G., Cocuzza C., Hopkins C., De Riu G., Piana A. F., Vaira, L, Deiana, G, Lechien, J, De Vito, A, Cossu, A, Dettori, M, Del Rio, A, Saussez, S, Madeddu, G, Babudieri, S, Fois, A, Cocuzza, C, Hopkins, C, De Riu, G, Piana, A, Vaira L. A., Deiana G., Lechien J. R., De Vito A., Cossu A., Dettori M., Del Rio A., Saussez S., Madeddu G., Babudieri S., Fois A. G., Cocuzza C., Hopkins C., De Riu G., and Piana A. F.

Abstract

Objectives/Hypothesis: The aim of this study was to evaluate the correlations between the severity and duration of olfactory dysfunctions (OD), assessed with psychophysical tests, and the viral load on the rhino-pharyngeal swab determined with a direct method, in patients affected by coronavirus disease 2019 (COVID-19). Study design: Prospective cohort study. Methods: Patients underwent psychophysical olfactory assessment with Connecticut Chemosensory Clinical Research Center test and determination of the normalized viral load on nasopharyngeal swab within 10 days of the clinical onset of COVID-19. Results: Sixty COVID-19 patients were included in this study. On psychophysical testing, 12 patients (20% of the cohort) presented with anosmia, 11 (18.3%) severe hyposmia, 13 (18.3%) moderate hyposmia, and 10 (16.7%) mild hyposmia with an overall prevalence of OD of 76.7%. The overall median olfactory score was 50 (interquartile range [IQR] 30–72.5) with no significant differences between clinical severity subgroups. The median normalized viral load detected in the series was 2.56E+06 viral copies/106 copies of human beta-2microglobulin mRNA present in the sample (IQR 3.17E+04–1.58E+07) without any significant correlations with COVID-19 severity. The correlation between viral load and olfactory scores at baseline (R2 = 0.0007; P =.844) and 60-day follow-up (R2 = 0.0077; P =.519) was weak and not significant. Conclusions: The presence of OD does not seem to be useful in identifying subjects at risk for being super-spreaders or who is at risk of developing long-term OD. Similarly, the pathogenesis of OD is probably related to individual factors rather than to viral load and activity. Level of Evidence: 4 Laryngoscope, 131:2312–2318, 2021.

Published
2021

11. Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis

Author

Singh, B., Lant, S., Cividini, S., Cattrall, J.W.S., Goodwin, L.C., Benjamin, L., Michael, B.D., Khawaja, A., Matos, A.D.B., Alkeridy, W., Pilotto, A., Lahiri, D., Rawlinson, R., Mhlanga, S., Lopez, E.C., Sargent, B.F., Somasundaran, A., Tamborska, A., Webb, G., Younas, K., Sami, Y. al, Babu, H., Banks, T., Cavallieri, F., Cohen, M., Davies, E., Dhar, S., Modol, A.F., Farooq, H., Harte, J., Hey, S., Joseph, A., Karthikappallil, D., Kassahun, D., Lipunga, G., Mason, R., Minton, T., Mond, G., Poxon, J., Rabas, S., Soothill, G., Zedde, M., Yenkoyan, K., Brew, B., Contini, E., Cysique, L., Zhang, X., Maggi, P., Pesch, V. van, Lechien, J., Saussez, S., Heyse, A., Ferreira, M.L.B., Soares, C.N., Elicer, I., Eugenin-von Bernhardi, L., Reyes, W.N., Yin, R., Azab, M.A., Abd-Allah, F., Elkady, A., Escalard, S., Corvol, J.C., Delorme, C., Tattevin, P., Bigaut, K., Lorenz, N., Hornuss, D., Hosp, J., Rieg, S., Wagner, D., Knier, B., Lingor, P., Winkler, A.S., Sharifi-Razavi, A., Moein, S.T., SeyedAlinaghi, S., JamaliMoghadamSiahkali, S., Morassi, M., Padovani, A., Giunta, M., Libri, I., Beretta, S., Ravaglia, S., Foschi, M., Calabresi, P., Primiano, G., Servidei, S., Mercuri, N.B., Liguori, C., Pierantozzi, M., Sarmati, L., Boso, F., Garazzino, S., Mariotto, S., Patrick, K.N., Costache, O., Pincherle, A., Klok, F.A., Meza, R., Cabreira, V., Valdoleiros, S.R., Oliveira, V., Kaimovsky, I., Guekht, A., Koh, J., Diaz, E.F., Barrios-Lopez, J.M., Guijarro-Castro, C., Beltran-Corbellini, A., Martinez-Poles, J., Diezma-Martin, A.M., Morales-Casado, M.I., Garcia, S.G., Breville, G., Coen, M., Uginet, M., Bernard-Valnet, R., Pasquier, R. du, Kaya, Y., Abdelnour, L.H., Rice, C., Morrison, H., Defres, S., Huda, S., Enright, N., Hassell, J., D'Anna, L., Benger, M., Sztriha, L., Raith, E., Chinthapalli, K., Nortley, R., Paterson, R., Chandratheva, A., Werring, D.J., Dervisevic, S., Harkness, K., Pinto, A., Jillella, D., Beach, S., Gunasekaran, K., Silva, I.R.F. da, Nalleballe, K., Santoro, J., Scullen, T., Kahn, L., Kim, C.Y., Thakur, K.T., Jain, R., Umapathi, T., Nicholson, T.R., Sejvar, J.J., Hodel, E.M., Smith, C.T., Solomon, T., Brain Infect Global COVID-Neuro Ne, University of Liverpool, Fondation Ophtalmologique Adolphe de Rothschild [Paris], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pontchaillou [Rennes], ARN régulateurs bactériens et médecine (BRM), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Les Hôpitaux Universitaires de Strasbourg (HUS), The study was funded by the UK Medical Research Council’s Global Effort on COVID-19 Programme (MR/V033441/1) (https://mrc.ukri.org/), UK National Institute for Health Research (NIHR)- funded Global Health Research Group on Acute Brain Infections (17/63/110) (https://www.nihr.ac.uk/), and the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections (NIHR200907), at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford (Grant Nos. IS-HPU-1112-10117 and NIHR200907). These grants were awarded to TS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
General Science & Technology, [SDV]Life Sciences [q-bio], Autonomic dysfunction, PROVISIONAL CASE DEFINITIONS, MESH: Hospitalization, MESH: Prognosis, MESH: Stroke, MESH: Risk Factors, Risk Factors, MESH: COVID-19, Humans, Multidisciplinary, Science & Technology, Hospitalization, Prognosis, COVID-19, Stroke, MESH: Humans, Metaanalysis, Hospitals, Brain Infections Global COVID-Neuro Network Study Group, Multidisciplinary Sciences, Medical risk factors, Settore MED/26 - NEUROLOGIA, Cerebrospinal fluid, Encephalitis, Science & Technology - Other Topics, Dementia
Abstract

Background Neurological COVID-19 disease has been reported widely, but published studies often lack information on neurological outcomes and prognostic risk factors. We aimed to describe the spectrum of neurological disease in hospitalised COVID-19 patients; characterise clinical outcomes; and investigate factors associated with a poor outcome. Methods We conducted an individual patient data (IPD) meta-analysis of hospitalised patients with neurological COVID-19 disease, using standard case definitions. We invited authors of studies from the first pandemic wave, plus clinicians in the Global COVID-Neuro Network with unpublished data, to contribute. We analysed features associated with poor outcome (moderate to severe disability or death, 3 to 6 on the modified Rankin Scale) using multivariable models. Results We included 83 studies (31 unpublished) providing IPD for 1979 patients with COVID-19 and acute new-onset neurological disease. Encephalopathy (978 [49%] patients) and cerebrovascular events (506 [26%]) were the most common diagnoses. Respiratory and systemic symptoms preceded neurological features in 93% of patients; one third developed neurological disease after hospital admission. A poor outcome was more common in patients with cerebrovascular events (76% [95% CI 67–82]), than encephalopathy (54% [42–65]). Intensive care use was high (38% [35–41]) overall, and also greater in the cerebrovascular patients. In the cerebrovascular, but not encephalopathic patients, risk factors for poor outcome included breathlessness on admission and elevated D-dimer. Overall, 30-day mortality was 30% [27–32]. The hazard of death was comparatively lower for patients in the WHO European region. Interpretation Neurological COVID-19 disease poses a considerable burden in terms of disease outcomes and use of hospital resources from prolonged intensive care and inpatient admission; preliminary data suggest these may differ according to WHO regions and country income levels. The different risk factors for encephalopathy and stroke suggest different disease mechanisms which may be amenable to intervention, especially in those who develop neurological symptoms after hospital admission.

Published
2022
Full Text
View/download PDF

17. Subjective evaluation of smell and taste dysfunction in patients with mild COVID-19 in Spain

Author

Ninchritz-Becerra E, Soriano-Reixach MM, Mayo-Yánez M, Calvo-Henríquez C, Martínez-Ruiz de Apodaca P, Saga-Gutiérrez C, Parente-Arias P, Villareal IM, Viera-Artiles J, Poletti-Serafini D, Alobid I, Ayad T, Saussez S, Lechien JR, and Chiesa-Estomba CM

Subjects
SARS-CoV-2, Anosmia, COVID-19, Ageusia
Abstract

Background: Has been described the loss of smell and taste as onset symptoms in SARS-CoV-2. The objective of this study was to investigate the prevalence in Spain. Methods: Prospective study of COVID-19 confirmed patients through RT-PCR in Spain. Patients completed olfactory and gustatory questionnaires. Results: A total of 1043 patients with mild COVID-19 disease. The mean age was 39 +/- 12 years. 826 patients (79.2%) described smell disorder, 662 (63.4%) as a total loss and 164 (15.7%) partial. 718 patients (68.8%) noticed some grade of taste dysfunction. There was a significant association between both disorders (p< .001). The olfactory dysfunction was the first symptom in 17.1%. The sQOD-NS scores were significantly lower in patients with a total loss compare to normosmic or hyposmic individuals (p = .001). Female were significantly more affected by olfactory and gustatory dysfunctions (p< .001). The early olfactory recover in 462 clinically cured patients was 315 (68.2%), during the first 4 weeks. Conclusion: The sudden onset smell and/or taste dysfunction should be considered highly suspicious for COVID-19 infection. (C) 2020 Elsevier Espaila, S.L.U. All rights reserved.

Published
2021

19. Systemic inflammatory markers and psychophysical olfactory scores in coronavirus disease 2019 patients: is there any correlation?

Author

Vaira, L A, primary, De Vito, A, additional, Deiana, G, additional, Pes, C, additional, Giovanditto, F, additional, Fiore, V, additional, Lechien, J R, additional, Saussez, S, additional, Policicchio, D, additional, Boccaletti, R, additional, Madeddu, G, additional, Babudieri, S, additional, Pazzola, A, additional, Bandiera, F, additional, Fois, A G, additional, Piana, A F, additional, Hopkins, C, additional, and De Riu, G, additional

Published
2021
Full Text
View/download PDF

26. Prevalence and 6‐month recovery of olfactory dysfunction: a multicentre study of 1363 COVID‐19 patients

Author

Lechien, J. R., primary, Chiesa‐Estomba, C. M., additional, Beckers, E., additional, Mustin, V., additional, Ducarme, M., additional, Journe, F., additional, Marchant, A., additional, Jouffe, L., additional, Barillari, M. R., additional, Cammaroto, G., additional, Circiu, M. P., additional, Hans, S., additional, and Saussez, S., additional

Published
2021
Full Text
View/download PDF

49. Expression of macrophage migration-inhibitory factor is correlated with progression in oral cavity carcinomas

Author

Kindt, N., Lechien, J., Christine Decaestecker, Rodriguez, A., Chantrain, G., Remmelink, M., Laurent, G., Gabius, H. -J, and Saussez, S.

Subjects
Inflammation, Dysplasia, Oto-rhino-laryngologie, animal diseases, Médecine pathologie humaine, chemical and pharmacologic phenomena, respiratory system, Prognosis, Tumor progression, biological factors, Cancérologie, Immunomodulation, otorhinolaryngologic diseases, Head and neck tumors, Cytokine
Abstract

We have previously reported that macrophage migration-inhibitory factor (MIF) is associated with an unfavorable prognosis in hypopharyngeal carcinoma. Here, we quantified MIF expression in oral cavity carcinomas and looked for possible correlations with clinical outcome., Journal Article, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2012

50. Galectin fingerprinting in Warthin's tumors: lectin-based approach to trace its origin?

Author

Saussez, S., Leval, L., Christine Decaestecker, Sirtaine, N., Stéphanie Cludts, Duray, A., Chevalier, D., André, S., Gabius, H. -J, Remmelink, M., and Leroy, X.

Subjects
Adenoma, stomatognathic diseases, Galectin, 61 - Medicina
Abstract

Warthin’s tumor of the parotid gland is assumed to originate from the proliferation of epithelial inclusions within parotid lymph nodes. In that case, these cells are supposed to retain characteristics similar to common salivary gland ductal cells. Using immunohistochemical fingerprinting with four members of the family of adhesion/growth-regulatory galectins and comparison to intra- and interlobular ducts, marked similarities were noted for presence of galectins-3, -7 and -8. Notably, profiles of lectin binding, determined by applying human lectins as probes, were also similar when testing biotinylated galectins-3 and -8. Besides defining the galectin histochemical parameters in Warthin’s tumors this study adds support to the hypothesis of heterotopia

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results